EP3277687B1 - 7-(morpholin-4-yl)pyrazole[1,5-a]pyrimidine derivatives which are useful for the treatment of immune or inflammatory diseases or cancer - Google Patents

7-(morpholin-4-yl)pyrazole[1,5-a]pyrimidine derivatives which are useful for the treatment of immune or inflammatory diseases or cancer Download PDF

Info

Publication number
EP3277687B1
EP3277687B1 EP16714019.3A EP16714019A EP3277687B1 EP 3277687 B1 EP3277687 B1 EP 3277687B1 EP 16714019 A EP16714019 A EP 16714019A EP 3277687 B1 EP3277687 B1 EP 3277687B1
Authority
EP
European Patent Office
Prior art keywords
morpholin
methyl
pyrazolo
pyrimidine
indol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP16714019.3A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP3277687A1 (en
Inventor
Barbara DYMEK
Marcin ZAGOZDA
Maciej Wieczorek
Krzysztof DUBIEL
Aleksandra Stanczak
Daria ZDZALIK
Pawel GUNERKA
Mariola SEKULAR
Maciej DZIACHAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celon Pharma SA
Original Assignee
Celon Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celon Pharma SA filed Critical Celon Pharma SA
Priority to SI201630560T priority Critical patent/SI3277687T1/sl
Priority to PL16714019T priority patent/PL3277687T3/pl
Publication of EP3277687A1 publication Critical patent/EP3277687A1/en
Application granted granted Critical
Publication of EP3277687B1 publication Critical patent/EP3277687B1/en
Priority to HRP20192195TT priority patent/HRP20192195T1/hr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Definitions

  • the present invention relates to novel 7-(morpholin-4-yl)pyrazolo[1,5- a ]pyrimidine derivatives, pharmaceutical compositions containing them, and their use as medicaments.
  • 7-(Morpholin-4-yl)pyrazolo[1,5- a ]pyrimidine derivatives exhibit the ability to inhibit PI3 kinase activity and can find use as medicaments, especially for treating immune system diseases, inflammatory diseases and cancer.
  • PI3 family of kinases are responsible for signal transduction on one of critical signaling pathways, responsible for regulation of cell survival, differentiation and migration processes. These kinases are also responsible for regulation of immune system function. Aberrant activation of PI3K pathway has been confirmed in oncological diseases, such as chronic lymphocytic leukemia or non-Hodgkin lymphoma, as well as in diseases with underlying inflammatory processes, such as for example rheumatoid arthritis or asthma.
  • Active kinases PI3 are composed of a catalytic subunit and a regulatory subunit.
  • PI3K type I family of kinases includes four regulatory subunits: PI3K- ⁇ , - ⁇ , - ⁇ , and - ⁇ .
  • Isoforms ⁇ and ⁇ are expressed in all tissues, and their inactivation at the embryonal development stage is lethal. Expression of isoforms ⁇ and ⁇ is limited to hematopoietic line; their inactivation is not lethal, resulting rather in occurrence of immunodeficiency syndrome in developing organisms.
  • Lipid kinases PI3 catalyze production of phosphatidylinositol (3,4,5)-trisphosphate (PIP 3 ) by phosphorylation of phosphatidylinositol via phosphatidylinositol 3-phosphate (PIP) and phosphatidylinositol 3,4-bisphosphate intermediates.
  • Phospholipid PIP 3 located in cellular membrane is a binding site for AKT protein, the degree of phosphorylation of which reflects the activity of PI3K pathway.
  • inhibition of PI3K is the attractive mechanism of treatment of many diseases, wherein the level phosphorylation of AKT protein in cells may play role.
  • PI3K ⁇ and ⁇ are highly expressed in a wide spectrum of tissues, as well as their role in embryonal development, non-selective PI3K inhibitors may have limited tolerability and high toxicity.
  • WO2010136491 and WO2010138589 disclose bicyclic indolopyrimidine compounds as exhibiting kinase PI3 inhibition activity and useful for treating diseases such as inflammatory and immunological disorders and cancers.
  • WO2011101429 discloses morpholino-substituted pyrido[3,2-d]pyrimidine compounds as exhibiting kinase PI3 inhibition activity and useful for treating diseases such as inflammatory and immunological disorders and cancers.
  • the object of the invention is the provision of novel compounds, PI3K inhibitors of potential utility in the treatment of inflammatory and immunological diseases and disorders, and cancers, exhibiting selective activity targeted at specific PI3K isoforms, in particular PI3K delta.
  • the present invention relates to a compound of the general formula (I) wherein:
  • the invention relates to the compound of the formula (I), wherein Y represents -CH 2 -.
  • One group of the compounds of the invention are the compounds of the formula (I), wherein R 3 represents H.
  • R 3 represents C1-C4 alkyl.
  • R 3 represents methyl.
  • Halogen atom encompasses chlorine, bromine and fluorine atoms, and advantageously represents chlorine atom.
  • R 2 represents B1.
  • R 2 represents B2.
  • R 5 in B2 represents -CR 6 R 7 R 8
  • R 8 , R 6 , R 7 and R 8 are independently selected from the group consisting of hydrogen atom and CH 3 , i.e.
  • R 5 represents C1-C4 alkyl selected from the group consisting of CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , and C(CH 3 ) 3 .
  • R 5 represents C(CH 3 ) 3 (t-butyl).
  • R 2 represents B3.
  • R 2 represents B4.
  • R 1 represents A1 or A2.
  • R 1 represents A1, wherein X 1 represents CH and X 2 represents CH or N.
  • R 1 represents A1, wherein X 1 represents CH and X 2 represents CH or N, and R 2 represents B2 or B4.
  • X 1 represents CH and X 2 represents CH.
  • Y represents -CH 2 -.
  • R 5 in B2 moiety represents C1-C4 alkyl, especially t-butyl.
  • R 10 in B4 moiety represents C1-C4 alkyl substituted with OH, especially 2-hydroxypropan-2-yl.
  • R 1 represents A1, wherein X 1 represents CH and X 2 represents CH or N, and R 2 represents B3 and Y represents -CH 2 -.
  • X 1 represents CH and X 2 represents CH.
  • R 1 represents A1, wherein X 1 represents N and X 2 represents CH, and R 2 represents B2 or B4.
  • Y represents -CH 2 -.
  • R 5 in B2 represents C1-C4 alkyl, especially t-butyl.
  • R 10 in B4 represents C1-C4 alkyl substituted with OH, especially 2-hydroxypropan-2-yl.
  • R 1 represents A1, wherein X 1 represents CH and X 2 represents C-O-CH 3 .
  • Y represents -CH 2 -.
  • R 5 in B2 represents C1-C4 alkyl, especially t-butyl.
  • R 10 in B4 represents C1-C4 alkyl substituted with OH, especially 2-hydroxypropan-2-yl.
  • R 4 represents C1-C4 alkyl, including methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl and t-butyl, especially methyl, ethyl or iso-propyl. Also preferably, R 4 represents cyclopropyl or cyclobutyl. Most preferably, R 4 is CHF 2 .
  • R 1 represents A2.
  • R 1 represents A2 wherein X 3 represents N, X 4 represents CH, X 5 represents CH, and X 6 represents CH, and R 2 represents B2 or B4.
  • Y represents -CH 2 -.
  • R 5 in B2 represents C1-C4 alkyl, especially t-butyl.
  • R 10 in B4 represents C1-C4 alkyl substituted with OH, especially 2-hydroxypropan-2-yl.
  • R 1 represents A2 wherein X 3 represents CH, X 4 represents N, X 5 represents CH, and X 6 represents CH, and R 2 represents B2 or B4.
  • Y represents -CH 2 -.
  • R 5 in B2 represents C1-C4 alkyl, especially t-butyl.
  • R 10 in B4 represents C1-C4 alkyl substituted with OH, especially 2-hydroxypropan-2-yl.
  • R 1 represents A2 wherein X 3 represents CH, X 4 represents CH, X 5 represents N, and X 6 represents CH, and R 2 represents B2 or B4.
  • Y represents -CH 2 -.
  • R 5 in B2 represents C1- C4 alkyl, especially t-butyl.
  • R 10 in B4 represents C1-C4 alkyl substituted with OH, especially 2-hydroxypropan-2-yl.
  • R 1 represents A2 wherein X 3 represents CH, X 4 represents CH, X 5 represents CH, and X 6 represents CH or CF, especially CH, and R 2 represents B2 or B4.
  • Y represents - CH 2 -.
  • R 5 in B2 represents C1-C4 alkyl, especially t-butyl.
  • R 10 in B4 represents C1-C4 alkyl substituted with OH, especially 2-hydroxypropan-2-yl.
  • R 1 represents A2 wherein X 3 represents CH, X 4 represents CH, X 5 represents CH and X 6 represents CH or CF, especially CH, and R 2 represents B2 or B4.
  • R 5 in B2 represents C1-C4 alkyl, especially t-butyl.
  • R 10 in B4 represents C1-C4 alkyl substituted with OH, especially 2-hydroxypropan-2-yl.
  • R 1 represents A2 wherein X 3 represents CH, X 4 represents CH, X 5 represents CF and X 6 represents CH, and R 2 represents B2 or B4.
  • R 5 in B2 represents C1-C4 alkyl, especially t-butyl.
  • R 10 in B4 represents C1-C4 alkyl substituted with OH, especially 2-hydroxypropan-2-yl.
  • R 1 represents A3 moiety
  • R 2 represents B2 or B4.
  • R 5 in B2 represents C1-C4 alkyl, especially t-butyl.
  • R 10 in B4 represents C1-C4 alkyl substituted with OH, especially 2-hydroxypropan-2-yl.
  • R 1 represents A1 or A2
  • R 2 represents B2 or B4.
  • R 5 in B2 represents tert-butyl
  • R 10 in B4 represents 2-hydroxypropan-2-yl.
  • C1-C4 alkyl used herein encompasses methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, and tert-butyl.
  • C1-C3 alkyl encompasses methyl, ethyl, n-propyl, and iso-propyl.
  • C1-C4 alkoxy encompasses methoxy, ethoxy, n-propoxy, n-butoxy, sec-butoxy, and tert-butoxy.
  • C3-C4-cycloalkyl encompasses cyclopropyl and cyclobutyl
  • C3-C5-cycloalkyl encompasses cyclopropyl, cyclobutyl, and cyclopentyl.
  • the compounds of the formula (I) of the invention exhibit the ability of PI3 kinase inhibition and can find use as medicaments, in particular for treating immune system diseases and disorders, inflammatory diseases and disorders, and cancer.
  • a specific characteristics of the compounds of the invention is high selectivity of kinase PI3K delta (PI3K ⁇ ) inhibition in comparison with other isoforms of this kinase. This allows to expect reduced toxicity in comparison with broad spectrum inhibitors acting on many PI3K isoforms.
  • Yet further aspect of the invention is therefore the use of the compound of the formula (I) as defined above for use in a method of treatment of immune system diseases and disorders, inflammatory diseases and disorders, and cancer.
  • Another aspect of the invention is a pharmaceutical composition
  • a pharmaceutical composition comprising the compound of the formula (I) as defined above and pharmaceutically acceptable excipients.
  • Acid addition salts of the compounds of the formula (I) of the invention include in particular salts with pharmaceutically acceptable inorganic or organic acids. Preferred are pharmaceutically acceptable acid addition salts. Inorganic and organic acids that are able to form acid addition salts, including pharmaceutically acceptable salts with the compounds having basic nitrogen atom and methods of their preparation are well known in the art. Salts with inorganic acids may in particular comprise salts of hydrochloric, hydrobromic, sulphuric and phosphoric acids.
  • Salts with organic acids may in particular comprise salts of methanesulphonic, ethanesulphonic, p-toluenesulphonic, benzenesulphonic, naphthalenesulphonic, acetic, propionic, lactic, tartaric, malic, citric, fumaric, maleic, and benzoic acids. It should be understood that the scope of the invention includes also salts with acids other than pharmaceutically acceptable ones that can be used especially as intermediates in the preparation, isolation and purification of the compounds of the invention.
  • Specific compounds of the invention are selected from the group consisting of the compounds presented below in the Examples and their acid addition salts, especially pharmaceutically acceptable acid addition salts, including inorganic and organic acids addition salts.
  • the compounds of formula (I) can be prepared in a manner described below generally and specifically in the examples of preparation of Intermediates and Compounds of the invention, and outlined in Schemes 1, 2 and 3. As shown in the above Scheme 1, the compounds of formula (I) wherein R 3 represents hydrogen atom or C1-C4 alkyl, and further symbols have the meaning as defined above, can be obtained from an aldehyde or acid of the formula (II) wherein Z represents hydrogen atom or OH, respectively, and further symbols have the meaning as defined for formula (I).
  • the reaction of reductive amination with amine R 2 H can be carried out in the temperature range from 0°C to the boiling point of the lowest boiling component of the reaction mixture, in an organic solvent such as for example chloroform, dichloromethane, dioxane, dimethylformamide, dimethylacetamide, toluene, hexane, tetrahydrofuran, or dimethoxyethane.
  • Reducing agent can be, for example, sodium borohydride, sodium triacetoxyborohydride, or sodium cyanohydride. Most suitable conditions are the use of dichloromethane as the solvent, sodium triacetoxyborohydride as the reducing agent, and carrying out the reaction at room temperature.
  • the amidation reaction with amine R 2 H can be carried out in the temperature range from 0°C to the boiling point of the lowest boiling component of the reaction mixture (reflux temperature), in an organic solvent such as, for example, chloroform, dichloromethane, dioxane, dimethylformamide, dimethylacetamide, toluene, hexane, tetrahydrofuran, dimethoxyethane, dimethylsulphoxide, ethyl acetate, acetonitrile or diethyl ether.
  • an organic solvent such as, for example, chloroform, dichloromethane, dioxane, dimethylformamide, dimethylacetamide, toluene, hexane, tetrahydrofuran, dimethoxyethane, dimethylsulphoxide, ethyl acetate, acetonitrile or diethyl ether.
  • the reaction is carried out in the presence of carbodiimide, for example N,N'-diisopropylcarbodiimide, N,N'-dicyclohexylcarbodiimide, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide chlorhydrate or 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate (HATU), an additive such as 1-hydroxybenzotriazole (HOBt) or N-hydroxysuccinimide, and tertiary amine such as, for example, triethylamine (TEA) or N,N-diisopropylethylamine (DIPEA).
  • carbodiimide for example N,N'-diisopropylcarbodiimide, N,N'-dicyclohexylcarbodiimide, 1-ethyl-3
  • the most suitable conditions for carrying out amidation are room temperature in dimethylformamide, in the presence of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDCI) hydrochloride, 1-hydroxybenzotriazole (HOBt) additive and triethylamine (TEA).
  • EDCI 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide
  • HOBt 1-hydroxybenzotriazole
  • TAA triethylamine
  • the compounds of formula (I) wherein R 3 represents halogen atom can be prepared by halogenation of the compounds of the formula (I) wherein R 3 represents hydrogen atom.
  • Halogenation reaction can be carried out using molecular halogen or N-halosuccinimide as a halogenating agent at the temperature in the range 0°C to the boiling point of the lowest boiling component of the mixture, in an organic solvent such as, for example, chloroform, dichloromethane, dioxane, dimethylformamide, dimethylacetamide, toluene, hexane, tetrahydrofuran, dimethoxyethane, dimethylsulphoxide, ethyl acetate, acetonitrile, or diethyl ether.
  • organic solvent such as, for example, chloroform, dichloromethane, dioxane, dimethylformamide, dimethylacetamide, toluene, hexane, tetrahydrofuran, dimethoxyethane, dimethylsulphoxide, ethyl acetate, acetonitrile, or diethyl ether.
  • the compounds of formula (II) are prepared from the compounds of the formula (III), wherein R 3 represents hydrogen atom or C1-C4 alkyl, and Bn represents benzyl, as outlined in Scheme 2.
  • palladium catalysts for example palladium acetate, tetrakis(triphenylphosphino)palladium(0), bis(triphenylphosphino)-palladium chloride, tris(dibenzylideneacetone)dipalladium(0), 1,1'-bis(diphenyl-phosphino)ferrocenepalladium(II) dichloride dichloromethane adduct, a base, for example sodium phosphate, sodium carbonate, potassium carbonate, cesium carbonate, or sodium acetate, and an organic solvent, for example toluene, hexane, tetrahydrofuran, dioxane, or 1,2-dimethoxyethane, at the temperature from the range 0°C to the boiling point of the lowest boiling component of the mixture.
  • organic solvent for example toluene, hexane, tetrahydrofuran, dioxane, or 1,2-dimethoxyethane,
  • the most suitable conditions of carrying out the reaction are tetrakis-(triphenylphosphino)palladium(0) as a catalyst, 2M aqueous sodium carbonate solution as a base, and 1,2-dimethoxyethane as a solvent at reflux temperature.
  • Removal of benzyl protecting group can be carried out by hydrogenation of the compound of the formula (IV) in the presence of palladium on active carbon, in an organic solvent such as, for example, methanol, ethanol, dimethylformamide, dioxane, cyclohexane, toluene, or their mixtures, at the temperature from 0°C to the boiling point of the lowest boiling component of the mixture, under hydrogen pressure in the range from 1 to 100 bar.
  • organic solvent such as, for example, methanol, ethanol, dimethylformamide, dioxane, cyclohexane, toluene, or their mixtures
  • the most suitable conditions of carrying out the reaction are dimethylformamide (DMF) and ethanol (EtOH) solvent mixture with the addition of formic acid, at elevated temperature, such about 60°C, under hydrogen pressure of about 1 bar.
  • the compound of the formula (V) thus obtained is converted into aldehyde or acid of the formula (II) by oxidation, using suitable oxidizing agents.
  • Compound of the formula (V) can be converted into aldehyde of the formula (II) by oxidation with Collins reagent, Dess-Martin reagent, pyridinium dichromate (PDC), pyridinium chlorochromate (PCC), 2-iodoxybenzoic acid (IBX), manganese dioxide or in the Swern reaction, in a solvent such as dichloromethane, acetonitrile, hexane, toluene, dimethylformamide (DMF), dimethylacetamide, dimethylsulphoxide (DMSO), or dioxane, at the temperature from 0°C to the boiling point of the lowest boiling component of the mixture.
  • the most suitable conditions of carrying out the reaction are the use of Dess-Martina reagent in a solvent such as DMF, at room temperature.
  • the compound of the formula (V) can be converted into acid of the formula (II) by oxidation with Jones reagent, potassium permanganate, pyridinium dichromate (PDC), ruthenium tetraoxide, 2,2,6,6-tetramethylpiperidinium N-oxide, in a solvent such as acetonitrile, water, toluene, acetone, dioxane, or tetrahydrofuran, at a temperature from 0°C to the boiling point of the lowest boiling component of the mixture.
  • PDC pyridinium dichromate
  • ruthenium tetraoxide 2,2,6,6-tetramethylpiperidinium N-oxide
  • a solvent such as acetonitrile, water, toluene, acetone, dioxane, or tetrahydrofuran
  • a palladium catalyst for example palladium acetate, tetrakis(triphenylphosphino)palladium(0), bis(triphenylphosphino)palladium chloride, tris(dibenzylideneacetone)dipalladium(0), 1,1'-bis(diphenylphosphino)ferrocenepalladium(II) dichloride dichloromethane adduct, a base, for example sodium phosphate, sodium carbonate, potassium carbonate, cesium carbonate, sodium acetate, sodium hydroxide, potassium hydroxide, sodium tert-butanolate, or potassium tert-butanolate, a phosphate ligand such as, for example, triphenylphosphine, 9,9-dimethyl-4,5-bis(diphenylphosphine)xanthene, (2-biphenyl)di-tert-butylphosphine
  • a phosphate ligand such as, for
  • the most suitable conditions of carrying out the reaction are reflux temperature in the presence of tris(dibenzylideneacetone)-dipalladium(0) as a catalyst, 9,9-dimethyl-4,5-bis(diphenylphosphine)xanthene, cesium carbonate, in toluene as a solvent.
  • the compound of the formula (VIII) is then subjected to amidation reaction with an acid of the formula R 4 COOH in a manner analogous to that described for the preparation of the compound of the formula (I) from the compound of the formula (II) when Z is hydroxyl group (-OH), to obtain a compound of the formula (IX).
  • the compound of the formula (IX) is converted to a compound of the formula (X) via cyclisation by heating at reflux in acetic acid.
  • benzyl group protecting hydroxyl group is removed from the compound (X), in a manner such as described above for deprotection of hydroxyl group in the compound of the formula (IV), to obtain a compound of the formula (XI) and compound of the formula (XI) thus obtained is converted by oxidation into an aldehyde or acid of the formula (II), wherein R 1 represents A1 group, using suitable oxidizing agent, as described above for oxidation of the compound of the formula (V).
  • a strong base such as sodium hydride
  • Nitrile of the formula (XII) is converted into compound of the formula (XIII) in cyclization reaction with hydrazine, analogously as described in WO2009/106539 .
  • Compound of the formula (XIII) by cyclization reaction with diethyl malonate in the presence of a strong base, such as sodium ethanolate, is converted into compound of the formula (XIV), which is further converted into compound of the formula (XV) by chlorination with phosphoryl trichloride (POCl 3 ), and then the compound of the formula (XV) is converted into compound of the formula (III) by reaction with morpholine in the presence of a base, such as sodium carbonate.
  • a base such as sodium carbonate
  • Intermediates of the formula R 2 H are either known compounds that are commercially available or can be obtained using known methods, in a manner presented in details below in the description of preparing Intermediates. In most cases, reductive amination reaction described above between a compound including carbonyl system and an appropriate amine was employed for preparing Intermediates R 2 H. For compounds R 2 H comprising urea system, a reaction between primary amine and isocyanate derivative was employed.
  • the reaction can be carried out at a temperature from -80°C to the boiling temperature of the lowest boiling component of the mixture, in an organic solvent, such as for example chloroform, dichloromethane, dioxane, dimethylformamide, dimethylacetamide, toluene, hexane, tetrahydrofuran, dimethoxyethane, dimethylsulphoxide, acetonitrile, or diethyl ether.
  • an organic solvent such as for example chloroform, dichloromethane, dioxane, dimethylformamide, dimethylacetamide, toluene, hexane, tetrahydrofuran, dimethoxyethane, dimethylsulphoxide, acetonitrile, or diethyl ether.
  • Boronic acids R 1 B(OH) 2 and their esters are commercially available or can be obtained using Miyaura reaction or in the reaction between haloderivative and boronic acid or its ester in the presence of a base or palladium catalyst.
  • Nitriles of the formula R 3 CH 2 CN, wherein R 3 represents hydrogen atom or C1-C4 alkyl, are known compounds that are commercially available.
  • the compounds of the formula (I) can be administered in the treatment of diseases and disorders mentioned herein as chemical compound or in the form of pharmaceutical composition or pharmaceutical formulation containing them. Typically, they will be used as pharmaceutical composition or pharmaceutical formulation containing the compound of the invention or its pharmaceutically acceptable salt, in combination with pharmaceutically acceptable carriers and auxiliary substances.
  • composition of the invention can be administered by any suitable route, preferably oral, parenteral or inhalation route and will be in the form of a preparation destined for use in medicine, depending on the intended administration route.
  • compositions for oral administration can have the form of solid or liquid preparations.
  • Solid preparations can have, for example, the form of a tablet or capsule produced in a conventional manner from pharmaceutically acceptable inactive excipients such as binders (for example, pregelatinised corn starch, polyvinylpyrrolidone or hydroxypropylmethylcellulose); fillers (for example lactose, saccharose, carboxymethylcellulose, microcrystalline cellulose or calcium hydrogenphosphate); disintegrants (for example crosspovidone, corn starch or sodium starch glycolate); lubricants (for example magnesium stearate, talc or silica), wetting agents (for example sodium laurylsulphate).
  • binders for example, pregelatinised corn starch, polyvinylpyrrolidone or hydroxypropylmethylcellulose
  • fillers for example lactose, saccharose, carboxymethylcellulose, microcrystalline cellulose or calcium hydrogenphosphate
  • disintegrants for example crosspovidone, corn starch or sodium starch
  • Tablets can be coated with coatings well known in the art, such as simple coatings, delayed/controlled-release coatings or enteric coatings.
  • Liquid preparations for oral administration can be in the form of, for example, solutions, syrups or suspensions, or can have the form of dry solid product for reconstitution in water or other suitable vehiculum before use.
  • Such liquid preparations can be prepared using conventional means from pharmaceutically acceptable inactive excipients, such as suspending agents (for example sorbitol syrup, cellulose derivatives or hydrogenated edible oils), emulsifiers (for example lecithine or acacia gum), nonaqueous vehicles (for example mandelic oil, oil esters, ethyl alcohol or fractionated vegetable oils), and preservatives (for example methyl or propyl p-hydroxybenzoate or sorbic acid).
  • suspending agents for example sorbitol syrup, cellulose derivatives or hydrogenated edible oils
  • emulsifiers for example lecithine or acacia gum
  • nonaqueous vehicles for example mandelic oil, oil esters, ethyl alcohol or fractionated vegetable oils
  • preservatives for example methyl or propyl p-hydroxybenzoate or sorbic acid.
  • Preparations can also include suitable buffering agents, flavoring agents, coloring agents and sweeteners.
  • Preparations for oral administration can be formulated so as to obtain controlled release of the active compound using methods known for a person skilled in the art.
  • compositions for parenteral administration can, for example, have the form of a unit dosage form, such as ampoules, or multi-dosage containers, with the addition of a preservative.
  • Compositions can have the form such as suspension, solution or emulsion in an oily or aqueous vehiculum, and can include excipients such as suspending agents, stabilizers, and/or dispersing agents.
  • the active ingredient can be formulated as a powder for reconstitution before use in a suitable carrier, for example sterile, pyrogen-free water.
  • compositions for administration via inhalation route can have the inhalation form and administered by nebulization.
  • Such preparations include an active compound and auxiliary substance(s) administered as an aerosol, i.e. a system of finely divided small particles of solid or liquid substance suspended in a gas.
  • auxiliary substances used in nebulization can be for example sodium chloride as an isotonicity agent, inorganic acids and hydroxides as pH regulators and stabilizers, benzalkonium chloride as a preservative, sodium citrate as a buffering agent, polysorbate 80 as a surfactant, ethanol and propylene glycol as a co-solvent, and sulphates (VI) as anti-oxidants.
  • Preparations for administration by inhalation route can have the form of pressure inhalers or dry powder inhalers.
  • the method of treatment with the use of the compounds of the present invention will comprise administration of a therapeutically effective amount of the compound of the invention, preferably in the form of a pharmaceutical composition, to the subject in need of such treatment.
  • Proposed dosage of the compounds of the invention is from 0.1 to about 1000 mg per day, in a single dose or in divided doses. It will be apparent for a person skilled in the art that selection of a dosage required for obtaining desirable biological effect will depend on many factors, for example specific compound, the indication, the manner of administration, the age and condition of a patient and that exact dosage will be ultimately determined by a responsible physician.
  • Step:1 To the solution of 0.50 g (2.0 mmol) of 1-benzhydrylazetidin-3-one in 20.0 ml of dry DCM 0.21 ml (0.209 g; 2.4 mmol) of morpholine were added, and then the mixture was stirred at room temperature. After 4 h 0.848 g (4.0 mmol) of sodium triacetoxyborohydride were added and stirring was continued at room temperature overnight. Water was added to the reaction mixture and phases were separated. Aqueous phase was extracted 3x with chloroform. Combined organic phases were dried over anhydrous sodium sulphate. The residue obtained after filtration of the drying agent and evaporation of the solvent under reduced pressure was purified on a chromatographic column.
  • Step 2 To the solution of 114 mg (0.37 mmol) of the product of Step 1 in 4 ml of EtOH 114 mg 10% Pd/C and 10 ⁇ l of formic acid were added. The reaction was carried out at room temperature under hydrogen pressure for 48 h. Catalyst was filtered on Celite®, the solid was washed with EtOH, and the filtrate was concentrated on evaporator. 50 mg (95%) of 4-(azetidin-3-yl)morpholine were obtained.
  • Example 70 2-(4- tert -butylpiperazin-1-ylcarbonyl)-5-(1 H -indol-4-yl)-7-(morpholin-4-yl)pyrazolo[1,5- a ]pyrimidine
  • reaction mixture was separated by column chromatography (silicagel modified with propylamine) using heptane/ethyl acetate from 100/0 to 0/100 system as an eluent. After separation 0.263 g (36%) of the compound 70 were obtained.
  • Tested compounds were dissolved in 100% DMSO, and thus obtained solutions were serially diluted in 1x reaction buffer.
  • Recombinant kinase was diluted in a reaction mixture comprising 5x reaction buffer, substrate (1mM sodium diacetate 4,5-bisphosphate phosphatydylinositol (PIP2) solution in 40mM Tris buffer), and water.
  • substrate 1mM sodium diacetate 4,5-bisphosphate phosphatydylinositol (PIP2) solution in 40mM Tris buffer
  • PIP2 sodium diacetate 4,5-bisphosphate phosphatydylinositol
  • Negative control wells contained all above reagents except tested compound and kinase, and positive control wells contained all above reagents except tested compounds.
  • Enzymatic reaction was initiated by adding 5 ⁇ l of 150 ⁇ M ATP solution, subsequently the plate was incubated for 1 hour at 25°C or 30°C (depending on PI3K isoform tested) in plate thermostat with orbital shaking of the plate contents at 600 rpm. Reaction conditions are presented below in Table 12.
  • Detection of ADP formed in the enzymatic reaction was then performed using ADP-Glo Kinase Assay (Promega).
  • ADP-Glo Kinase Assay Promega.
  • To the wells of a 96-well plate 25 ⁇ l of ADP-Glo Reagent were added, and the plate was incubated for 40 minutes at 25°C in a plate thermostat with orbital shaking at 600 rpm. Then to the wells of 96-well plate 50 ⁇ l of Kinase Detection Reagent were added and the plate was incubated for 40 minutes at 25°C in a plate thermostat with orbital shaking at 600 rpm. After incubation time, luminescence intensity in a well was measured by Victor Light luminometer (Perkin Elmer, Inc.).
  • IC 50 values were determined on the basis of luminescence intensity measurements in wells containing tested compounds at different concentrations and in control wells. These values were calculated with Graph Pad 5.03 software by fitting the curve using non-linear regression. Each compound was tested at least in quadruplicates (4 wells) on two 96-well plates using at least 4 wells of each of the controls.
  • the AKT protein phosphorylation level in a cell depends on the activity of PI3K pathway - inhibition of PI3K kinases with an inhibitor (tested compound) results in decrease of AKT phosphorylation that can be seen in a Western blot method as disappearance of a lane stained with anti-pAKT antibodies. Inhibition of kinases does not influence the total protein level; staining with anti-pAKT antibodies is a control in the experiment. Control for each staining is the measurement of the level of glyceraldehyde 3-phosphate dehydrogenase (GAPDH), the protein present in cells in a constant amount.
  • GPDH glyceraldehyde 3-phosphate dehydrogenase
  • RAJI cell line (origin: Burkitt lymphoma, supplier: ATCC) stimulated with IgM antibody was used. This antibody, by binding with BCR receptor present on a surface of these cells, causes PI3K ⁇ activation and in turn increase of AKT phosphorylation ( Winkler et al. 2013, Chemistry and Biology ).
  • RAW264.7 cell line (origin: Ab-MLB transformed murine lymphocytes line, supplier: ATCC), stimulated with C5a component of the complement system.
  • This protein by binding with C5aR receptor, causes activation of PI3K ⁇ , this in turn resulting in increase of AKT phosphorylation level ( Winkler et al. 2013, Chemistry and Biology ).
  • Cells were seeded onto 6-well plates at a density 1-1.5x10 6 /ml in a culture without inhibitor. Directly after seeding cells were treated with tested compounds for 1 hour, and then cells were stimulated (Raji: anti-IgM, 5mg/ml, 15min before the end of incubation; RAW: C5a, 5ng/ml, 5min before the end of incubation). Then the cells were lysed with RIPA buffer (Sigma-Aldrich) containing proteases inhibitors (Halt Protease Inhibitor Cocktail, Thermo) and phosphatases (PhosSTOP, Roche) and protein concentration was determined using BCA method (Pierce) in accordance with manufacturer's recommendations.
  • RIPA buffer Sigma-Aldrich
  • proteases inhibitors Halt Protease Inhibitor Cocktail, Thermo
  • PhosSTOP phosphatases
  • Obtained lysates were subjected to SDS-PAGE electrophoresis for 2 hours at 100 V in Mini Protean III (BioRad) apparatus. Following electrophoresis, separated proteins were transferred onto nitrocellulose membrane by electrotransfer technique for 1 hour at 100 V in Mini Protean III apparatus. Western blot analysis of selected proteins was performed in accordance with antibodies manufacturer's recommendations.
  • Fig. 3 shows dose-dependent decrease of PI3K delta activity as a decreasing intensity of a lane for phospho-AKT protein (line RAJI).
  • line RAJI phospho-AKT protein
  • Tests were performed on about 12 weeks old Wistar rats, weight 250-300 g. Rats were given orally tested compounds at 30 mg/kg m.c. Blood samples were collected from animals for analysis in 6 time points - 30 min, 1h, 2h, 4h, 7h, and 12h from administration of the compound. Blood was collected to tubes with K2EDTA and centrifuged for 15min, 2000xg, at room temperature to separate serum. Collected serum samples were maintained at -20°C before analysis. Each of the compounds was tested on a group of 5 animals.
  • Serum concentrations of tested compounds were determined by spectrophotometry. For each of tested compounds, time to reach maximum serum concentration (Tmax), maximum concentration (Cmax), and area under the curve (AUC) were determined.
  • Pharmacokinetic parameters for four representative compounds of the present invention are presented in Table 14: Table 14.
  • Tested compounds are bioavailable and reach Tmax and Cmax typical for medicaments in this class.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EP16714019.3A 2015-04-02 2016-03-30 7-(morpholin-4-yl)pyrazole[1,5-a]pyrimidine derivatives which are useful for the treatment of immune or inflammatory diseases or cancer Active EP3277687B1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
SI201630560T SI3277687T1 (sl) 2015-04-02 2016-03-30 7-(morfolin-4-IL)pirazol(1,5-A)pirimidinski derivati, ki so uporabni za zdravljenje imunskih ali vnetnih bolezni ali raka
PL16714019T PL3277687T3 (pl) 2015-04-02 2016-03-30 Pochodne 7-(morfolin-4-ylo)pirazolo[1,5-a]pirymidyny użyteczne do leczenia chorób immunologicznych lub zapalnych lub nowotworów
HRP20192195TT HRP20192195T1 (hr) 2015-04-02 2019-12-06 Derivati 7-(morfolin-4-il)pirazol[1,5-a]pirimidina koji su korisni za liječenje imunoloških ili upalnih oboljenja ili karcinoma

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PL411864A PL236355B1 (pl) 2015-04-02 2015-04-02 Pochodne 7-(morfolin-4-ylo)pirazolo[1,5-α]pirymidyny jako inhibitory kinazy PI3
PCT/IB2016/051792 WO2016157091A1 (en) 2015-04-02 2016-03-30 7-(morpholin-4-yl)pyrazole[1,5-a]pyrimidine derivatives which are useful for the treatment of immune or inflammatory diseases or cancer

Publications (2)

Publication Number Publication Date
EP3277687A1 EP3277687A1 (en) 2018-02-07
EP3277687B1 true EP3277687B1 (en) 2019-10-30

Family

ID=55650626

Family Applications (1)

Application Number Title Priority Date Filing Date
EP16714019.3A Active EP3277687B1 (en) 2015-04-02 2016-03-30 7-(morpholin-4-yl)pyrazole[1,5-a]pyrimidine derivatives which are useful for the treatment of immune or inflammatory diseases or cancer

Country Status (18)

Country Link
US (1) US10138247B2 (ja)
EP (1) EP3277687B1 (ja)
JP (1) JP6665201B2 (ja)
KR (1) KR102559190B1 (ja)
CN (1) CN107743489B (ja)
AU (1) AU2016241568B2 (ja)
BR (1) BR112017020131B1 (ja)
CA (1) CA2978828A1 (ja)
DK (1) DK3277687T3 (ja)
EA (1) EA032826B1 (ja)
ES (1) ES2765642T3 (ja)
HR (1) HRP20192195T1 (ja)
HU (1) HUE047822T2 (ja)
MX (1) MX2017011423A (ja)
PL (2) PL236355B1 (ja)
PT (1) PT3277687T (ja)
SI (1) SI3277687T1 (ja)
WO (1) WO2016157091A1 (ja)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11834467B2 (en) 2020-09-28 2023-12-05 1ST Biotherapeutics, Inc. Substituted indazoles as hematopoietic progenitor kinase 1 (HPK1) inhibitors
CN114957261B (zh) * 2022-05-17 2023-06-23 重庆文理学院 一种具有抗头颈癌作用的化合物及其制备方法和应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL191271B1 (pl) * 1996-02-07 2006-04-28 Neurocrine Biosciences Inc Pochodna pirazolopirymidyny i jej zastosowanie oraz kompozycja farmaceutyczna
CA2550729A1 (en) 2003-12-23 2005-07-14 Activbiotics, Inc. Rifamycin analogs and uses thereof
CN101115755B (zh) * 2005-02-11 2013-01-16 弗·哈夫曼-拉罗切有限公司 作为mglur2拮抗剂的吡唑并-嘧啶衍生物
DK2094709T3 (da) * 2006-09-20 2010-12-06 Lilly Co Eli Thiazol-pyrazolopyrimidiner som CRF1-receptorantagonister
WO2009053716A1 (en) * 2007-10-26 2009-04-30 F.Hoffmann-La Roche Ag Purine derivatives useful as pi3 kinase inhibitors
MX2010009416A (es) 2008-02-26 2010-09-24 Novartis Ag Compuestos heterociclicos como inhibidores de cxcr2.
JP2011521968A (ja) * 2008-05-30 2011-07-28 ジェネンテック， インコーポレイテッド プリンｐｉ３ｋ阻害剤化合物および使用方法
WO2010037765A2 (en) * 2008-10-03 2010-04-08 Merck Serono S.A. 4-morpholino-pyrido[3,2-d]pyrimidines
WO2010074284A1 (ja) * 2008-12-26 2010-07-01 味の素株式会社 ピラゾロピリミジン化合物
BRPI1014572B8 (pt) * 2009-04-16 2022-07-19 Fundacion Centro Nac De Investigaciones Oncologicas Carlos Iii Imidazopirazinas para uso como inibidores de cinase
CA2761445A1 (en) * 2009-05-27 2010-12-02 Genentech, Inc. Bicyclic pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use
CA2772371A1 (en) 2009-05-27 2010-12-02 F. Hoffmann-La Roche Ag Bicyclic indole-pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use
GB0912745D0 (en) 2009-07-22 2009-08-26 Wolfson Microelectronics Plc Improvements relating to DC-DC converters
CA2786294A1 (en) 2010-02-22 2011-08-25 F. Hoffmann-La Roche Ag Pyrido[3,2-d]pyrimidine pi3k delta inhibitor compounds and methods of use
WO2011109267A1 (en) 2010-03-04 2011-09-09 Merck Sharp & Dohme Corp. Inhibitors of catechol o-methyl transferase and their use in the treatment of psychotic disorders
US9096605B2 (en) * 2011-08-24 2015-08-04 Glaxosmithkline Llc Pyrazolopyrimidine derivatives as PI3 kinase inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
None *

Also Published As

Publication number Publication date
KR20170132275A (ko) 2017-12-01
SI3277687T1 (sl) 2020-02-28
MX2017011423A (es) 2018-05-17
KR102559190B1 (ko) 2023-07-25
CN107743489A (zh) 2018-02-27
ES2765642T3 (es) 2020-06-10
PL236355B1 (pl) 2021-01-11
AU2016241568A1 (en) 2017-10-19
JP6665201B2 (ja) 2020-03-13
EA032826B1 (ru) 2019-07-31
CN107743489B (zh) 2021-05-04
AU2016241568B2 (en) 2019-09-26
CA2978828A1 (en) 2016-10-06
PL411864A1 (pl) 2016-10-10
BR112017020131A2 (pt) 2018-05-29
DK3277687T3 (da) 2019-12-16
EA201792087A1 (ru) 2018-03-30
HUE047822T2 (hu) 2020-05-28
EP3277687A1 (en) 2018-02-07
WO2016157091A1 (en) 2016-10-06
US20180111939A1 (en) 2018-04-26
JP2018510192A (ja) 2018-04-12
PL3277687T3 (pl) 2020-09-21
BR112017020131B1 (pt) 2023-02-28
HRP20192195T1 (hr) 2020-03-06
US10138247B2 (en) 2018-11-27
PT3277687T (pt) 2020-01-10

Similar Documents

Publication Publication Date Title
US9834560B2 (en) Compounds
EP2588466B1 (en) 5-Amino-3,6-dihydro-1H-pyrazin-2-one derivatives useful as inhibitors of beta-secretase (BACE)
CN108699062B (zh) 四氢吡喃基氨基-吡咯并嘧啶酮及其使用方法
JP6298998B2 (ja) ウイルス感染を治療するための１，２，４−トリアジン誘導体
WO2009122180A1 (en) Pyrimidine derivatives capable of inhibiting one or more kinases
US20210340102A1 (en) Substituted 6,11-dihydro-5h-benzo[b]carbazoles as inhibitors of alk and srpk
WO2005085252A1 (en) Imidazo ‘1,2-a’ pyrazine compounds which interact with protein kinases
JP5509070B2 (ja) 神経変性疾患の治療のためのアリールアミドピリミドン誘導体
US20230312557A1 (en) P2x3 modulators
JP2019524678A (ja) ヘッジホッグ経路アンタゴニスト活性を持つキラル複素環式化合物、及びその製造方法、並びに応用
EP3277687B1 (en) 7-(morpholin-4-yl)pyrazole[1,5-a]pyrimidine derivatives which are useful for the treatment of immune or inflammatory diseases or cancer
CN109641909B (zh) 雷帕霉素信号通路抑制剂的机理靶标及其治疗应用
WO2023244946A1 (en) Prodrugs of stat3 inhibitors
JP2024534169A (ja) Ｅｇｆｒ阻害剤としての置換アミノピリジン化合物
KR20230163466A (ko) Ddr1 및 ddr2 억제제로서의 인돌린 유도체
KR20220123446A (ko) Btk 억제제
KR20210149077A (ko) 포스포이노시타이드 3-키나아제 억제제로서 아이소크로멘 유도체
US20240116947A1 (en) Pyrido oxazine derivatives as alk5 inhibitors
WO2024097355A1 (en) Deubiquitinase-targeting chimeras and related methods
CN117143107A (zh) 1,2-二氢吡啶类衍生物及其制备方法和用途
NZ795496A (en) Aminothiazole compounds as c-Kit inhibitors
WO2015016729A1 (en) Urea compounds and their use as faah enzyme inhibitors

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20171006

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20190121

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20190716

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1196005

Country of ref document: AT

Kind code of ref document: T

Effective date: 20191115

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602016023286

Country of ref document: DE

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: HR

Ref legal event code: TUEP

Ref document number: P20192195T

Country of ref document: HR

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Effective date: 20191211

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Ref document number: 3277687

Country of ref document: PT

Date of ref document: 20200110

Kind code of ref document: T

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20191223

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: RO

Ref legal event code: EPE

REG Reference to a national code

Ref country code: NO

Ref legal event code: T2

Effective date: 20191030

REG Reference to a national code

Ref country code: SK

Ref legal event code: T3

Ref document number: E 33073

Country of ref document: SK

REG Reference to a national code

Ref country code: HR

Ref legal event code: T1PR

Ref document number: P20192195

Country of ref document: HR

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20192195

Country of ref document: HR

Payment date: 20200319

Year of fee payment: 5

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20190403956

Country of ref document: GR

Effective date: 20200318

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191030

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191030

REG Reference to a national code

Ref country code: HU

Ref legal event code: AG4A

Ref document number: E047822

Country of ref document: HU

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191030

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200229

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2765642

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20200610

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191030

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191030

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602016023286

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191030

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20200731

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191030

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200330

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20192195

Country of ref document: HR

Payment date: 20210323

Year of fee payment: 6

REG Reference to a national code

Ref country code: AT

Ref legal event code: UEP

Ref document number: 1196005

Country of ref document: AT

Kind code of ref document: T

Effective date: 20191030

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20192195

Country of ref document: HR

Payment date: 20220321

Year of fee payment: 7

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191030

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191030

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191030

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20192195

Country of ref document: HR

Payment date: 20230322

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: RO

Payment date: 20230323

Year of fee payment: 8

Ref country code: NO

Payment date: 20230321

Year of fee payment: 8

Ref country code: IE

Payment date: 20230320

Year of fee payment: 8

Ref country code: FR

Payment date: 20230320

Year of fee payment: 8

Ref country code: FI

Payment date: 20230320

Year of fee payment: 8

Ref country code: DK

Payment date: 20230323

Year of fee payment: 8

Ref country code: CZ

Payment date: 20230320

Year of fee payment: 8

Ref country code: BG

Payment date: 20230317

Year of fee payment: 8

Ref country code: AT

Payment date: 20230317

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: TR

Payment date: 20230327

Year of fee payment: 8

Ref country code: SK

Payment date: 20230317

Year of fee payment: 8

Ref country code: SI

Payment date: 20230320

Year of fee payment: 8

Ref country code: SE

Payment date: 20230315

Year of fee payment: 8

Ref country code: PT

Payment date: 20230324

Year of fee payment: 8

Ref country code: HU

Payment date: 20230329

Year of fee payment: 8

Ref country code: HR

Payment date: 20230322

Year of fee payment: 8

Ref country code: GR

Payment date: 20230317

Year of fee payment: 8

Ref country code: GB

Payment date: 20230323

Year of fee payment: 8

Ref country code: BE

Payment date: 20230321

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20230322

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20230331

Year of fee payment: 8

Ref country code: ES

Payment date: 20230414

Year of fee payment: 8

Ref country code: CH

Payment date: 20230402

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PL

Payment date: 20240307

Year of fee payment: 9

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20240330

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20240330

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20240923

Year of fee payment: 9